All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development in UNITED KINGDOM

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Immune Regulation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Chemspec USA 2020

Participation Not Confirmed

Update your events

Immune Regulation and DynPort to Trial Covid-19 Drug Candidate

Contact the Supplier

Lead Product(s): ILR201104

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ILR201104

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: DynPort

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 06, 2020

Details:

The Immune Regulation entered into a Teaming Agreement with DynPort Vaccine Company LLC to jointly evaluate the potential of Immune Regulation’s drug product ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS) in US clinical trials.

Redx Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Chemspec USA 2020

Participation Not Confirmed

Update your events

Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis

Contact the Supplier

Lead Product(s): RXC007

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.